Merck has announced that the Phase 3 Trofuse-005 trial evaluating Sacituzumab Tirumotecan (Sac-TMT) successfully met its primary endpoints, offering a new hope for patients with advanced or metastatic NSCLC.
Novartis has announced groundbreaking results from the Phase III PSMAddition trial, revealing that Pluvicto significantly reduces the risk of PSA progression by 58% in patients with metastatic hormone-sensitive prostate cancer.
AstraZeneca and Daiichi Sankyo’s Enhertu achieves milestone FDA approvals in two early-stage HER2-positive breast cancer settings, reshaping curative care.
The Phase III VOLGA trial has reached its primary endpoints, proving that the Imfinzi EV bladder cancer combination delivers historic survival gains in the perioperative setting.
Labcorp has announced nationwide availability for the Agilent PD-L1 IHC 22C3 pharmDx, a critical companion diagnostic for identifying ovarian cancer patients eligible for Merck’s KEYTRUDA therapy.
Pfizer and Merck announce that the FDA has accepted a supplemental Biologics License Application (sBLA) for PADCEV in combination with KEYTRUDA for Priority Review in patients with muscle-invasive bladder cancer (MIBC).
Topline results from the Phase 3 BRUIN CLL-322 trial confirm that Jaypirca significantly extended progression-free survival when added to a venetoclax regimen.
AbbVie presented late-breaking Phase 2 data at SGO 2026 showing that Mirvetuximab Soravtansine PSOC treatment combined with carboplatin achieved a 62.7% response rate in FRα-high patients, offering a new hope for platinum-sensitive recurrence.
AstraZeneca announces positive results from the EMERALD-2 Phase III trial, proving that the Imfinzi and Imjudo liver cancer treatment significantly delays disease recurrence in patients following surgery or ablation.
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data from the ARTEMIS-001 trial, this B7-H3-targeted antibody-drug conjugate aims to transform the prognosis for patients with extensive-stage disease, who currently face a median survival of just 8 months. This marks the sixth major global regulatory designation for risvutatug rezetecan, signaling its critical role in the future of oncology.
